Compare AbbVie Inc (ABBV) vs Omnicom Group Inc. (OMC) Price & Performance

AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.

The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.

OMC trades at $80.84, up 2.82% today, with a bullish technical outlook supported by moving averages and a consensus price target of $105.75. Recent Q1 2026 earnings beat expectations with EPS of $1.90 versus $1.82 expected, while revenue grew to $17.27B in 2025. The company announced new partnerships with IBM and Netflix, enhancing its media agency footprint, and declared a $0.80 dividend payable in July 2026.

The stock presents value with a low P/E of 12.16 and P/S of 0.93, but net income turned negative in 2025, posing a risk. Analyst sentiment is mixed with 32% buy ratings, reflecting optimism about growth initiatives against profitability concerns. Investors should weigh the attractive valuation and strong cash flow against execution risks in a competitive advertising market.